Vktx stock forecast 2030 the vktx stock forecast 2030 reflects

The vktx stock forecast 2030 reflects expectations of double-digit CAGR driven by late-stage clinical trial successes in NASH and obesity treatments. Current market cap growth trends and solid cash reserves position the stock for potential outsized returns if FDA approvals hit as expected. Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical trials of two formulations of its leading weight loss drug candidate. In fact, after the first data report in late February, the stock surged 120% in just one trading session. It has maintained much of that gain in the weeks that followed, and today is up by almost 100% since the report. If Casgevy reaches its peak potential while CRISPR Therapeutics continues to advance programs through the pipeline, the result could be outsized returns for shareholders. Options market activity shows increasing open interest in long-dated calls, signaling that sophisticated traders are positioning for an upside into the decade. This supports bullish scenarios in the vktx stock forecast 2030 outlook favored by growth-focused biotech investors.